Patents by Inventor Benjamin Whalley
Benjamin Whalley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220265573Abstract: The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidivarin (6-OH CBDV), is a metabolite of cannabidivarin (CBDV). The cannabinoid can be produced by synthetic means and a method for the production of 6-OH CBDV is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-OH CBDV in a model of disease.Type: ApplicationFiled: May 13, 2022Publication date: August 25, 2022Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
-
Patent number: 11419829Abstract: The present invention relates to the use of cannabidiol (CBD) in combination with an agonist of 5-HT2B receptors. Such a combination provides protection against the adverse effects caused by agonists of 5-HT2B receptors. The invention further relates to the use of CBD in combination5 with an amphetamine or amphetamine derivative in the treatment of epilepsy. In one embodiment the CBD is used in combination with the amphetamine derivative fenfluramine to produce a significant reduction in seizures. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid10 tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.Type: GrantFiled: October 1, 2018Date of Patent: August 23, 2022Assignee: GW Research LimitedInventors: Benjamin Whalley, Geoffrey Guy, Volker Knappertz, Royston Gray, Rohini Rana
-
Publication number: 20220249396Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking one or more antiepileptic drugs that works via GABA receptor agonism. Preferably the AED is stiripentol. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterized. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.Type: ApplicationFiled: December 16, 2021Publication date: August 11, 2022Inventors: Geoffrey GUY, Voiker KNAPPRTZ, Benjamin WHALLEY
-
Publication number: 20220226257Abstract: The present invention relates to the use of a specific composition of cannabidiol (CBD) in the treatment of comorbidities associated with epilepsy. In one embodiment the comorbidities are surprisingly found to be improved patients where there is as absence of reduction in seizures. The CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) is present in an amount of from 0.02 to 0.1% (w/w).Type: ApplicationFiled: January 16, 2020Publication date: July 21, 2022Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLEY-ROBERTS
-
Publication number: 20220184000Abstract: The present invention relates to the use of cannabidiol (CBD) for use in the treatment of disease modification in Dravet syndrome. In particular the CBD is used to improve neonatal welfare, survival and co-morbidities in patients with Dravet syndrome. Preferably the CBD used is in the form of a botanically derived purified CBD which comprises greater titan or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. The other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-C1 at a concentration of less titan or equal to 0.15% (w/w); CBDV at a concentration of less titan or equal to 0.8% (w/w); and CBD-C4 at a concentration of less than or equal to 0.4% (w/w). The botanically derived purified CBD preferably also comprises a mixture of both trans-THC and cis-THC. Alternatively, a synthetically produced CBD is used.Type: ApplicationFiled: July 27, 2020Publication date: June 16, 2022Inventors: Geoffrey GUY, Benjamin WHALLEY, Pabitra PATRA
-
Publication number: 20220168266Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(IR,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.Type: ApplicationFiled: November 17, 2021Publication date: June 2, 2022Inventors: Geoffrey GUY, Volker KNAPP ERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS, James BRODIE, Katarzyna LACH-FALCONE, Alan SUTTON, Royston GRAY, Rohini Rajyalaxmi RANA
-
Patent number: 11318109Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).Type: GrantFiled: December 10, 2019Date of Patent: May 3, 2022Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., LimitedInventors: Benjamin Whalley, Claire Williams, Gary Stephens, Thomas Hill
-
Publication number: 20220062211Abstract: The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.Type: ApplicationFiled: September 9, 2021Publication date: March 3, 2022Inventors: Colin STOTT, Nicholas JONES, Robin WILLIAMS, Benjamin WHALLEY
-
Publication number: 20220062197Abstract: The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.Type: ApplicationFiled: September 10, 2021Publication date: March 3, 2022Inventors: Colin STOTT, Nick Jones, Benjamin Whalley, Gary Stephens, Claire Williams
-
Publication number: 20220016048Abstract: The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C4 (CBD-C4), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means. Disclosed herein are data which demonstrate the efficacy of CBD-C4 in models of disease. In addition, a method for the production of CBD-C4 is described.Type: ApplicationFiled: November 20, 2019Publication date: January 20, 2022Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Royston GRAY, Jacqueline CILIA, Amesha PATEL, Hannah STRAKER
-
Patent number: 11207292Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.Type: GrantFiled: September 3, 2020Date of Patent: December 28, 2021Assignee: GW Research LimitedInventors: Geoffrey Guy, Volker Knappertz, Benjamin Whalley, Marie Woolley-Roberts, James Brodie, Katarzyna Lach-Falcone, Alan Sutton, Royston Gray, Rohini Rajyalaxmi Rana
-
Patent number: 11147783Abstract: The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.Type: GrantFiled: July 29, 2016Date of Patent: October 19, 2021Assignee: GW Research LimitedInventors: Colin Stott, Nicholas Jones, Robin Williams, Benjamin Whalley
-
Patent number: 11147776Abstract: The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.Type: GrantFiled: October 3, 2019Date of Patent: October 19, 2021Assignee: GW Research LimitedInventors: Colin Stott, Nick Jones, Benjamin Whalley, Gary Stephens, Claire Williams
-
Publication number: 20210077455Abstract: The present invention relates to the use of cannabinoids in the treatment of a neurodegenerative disease or disorder. In particular the cannabinoids cannabidiolic acid (CBDA) and cannabidivarin (CBDV) were able to produce neuroprotective effects in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with amyotrophic lateral sclerosis (ALS). Furthermore, the combination of the cannabinoid tetrahydrocannabinol (THC) with the drug olexisome provided a synergistic disease modifying effect in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with ALS.Type: ApplicationFiled: July 10, 2018Publication date: March 18, 2021Applicant: GW Research LimitedInventors: Benjamin Whalley, William Hind, Royston Gray, Javier Fernandez-Ruiz, Eva De Lago, Carmen Rodriguez-Cueto, Laura Garcia-Toscano, Irene Santos-Garcia
-
Publication number: 20210052512Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.Type: ApplicationFiled: April 26, 2019Publication date: February 25, 2021Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS, James BRODLE, Katarzyna LACH-FALCONE, Alan SUTTON, Royston GRAY, Rohini Rajyalaxmi RANA
-
Publication number: 20210015789Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.Type: ApplicationFiled: September 3, 2020Publication date: January 21, 2021Inventors: Geoffrey GUY, Volker Knappertz, Benjamin Whalley, Marie Woolley-Roberts, James Brodie, Katarzyna Lach-Falcone, Alan Sutton, Royston Gray, Rohini Rajyalaxmi Rana
-
Publication number: 20200352878Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking one or more antiepileptic drugs that works via GABA receptor agonism. Preferably the AED is stiripentol. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.Type: ApplicationFiled: January 22, 2019Publication date: November 12, 2020Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY
-
Patent number: 10729665Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).Type: GrantFiled: September 14, 2012Date of Patent: August 4, 2020Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., LimitedInventors: Benjamin Whalley, Claire Williams, Gary Stephens, Thomas Hill
-
Publication number: 20200237683Abstract: The present invention relates to the use of cannabidiol (CBD) in combination with an agonist of 5-HT2B receptors. Such a combination provides protection against the adverse effects caused by agonists of 5-HT2B receptors. The invention further relates to the use of CBD in combination5 with an amphetamine or amphetamine derivative in the treatment of epilepsy. In one embodiment the CBD is used in combination with the amphetamine derivative fenfluramine to produce a significant reduction in seizures. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid10 tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.Type: ApplicationFiled: October 1, 2018Publication date: July 30, 2020Inventors: Benjamin WHALLEY, Geoffrey GUY, Volker KNAPPERTZ, Royston GRAY, Rohini RANA
-
Publication number: 20200206153Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of tumours associated with Tuberous Sclerosis Complex (TSC). In particular the CBD was able to decrease the number and size of marker cells, pS6, in a zebrafish model of TSC. This is5 suggestive of a disease modifying effect whereby treatment with CBD could result in the reduction or prevention of the benign tumours that occur in TSC patients. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially 10 removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD. In use the CBD is given concomitantly with one or more other drugs used in the treatment of TSC.Type: ApplicationFiled: June 21, 2018Publication date: July 2, 2020Inventors: Benjamin WHALLEY, William HIND, Royston GRAY, Michael BAZELOT, Ines De SILVA SERRA, Claire WILLIAMS, Andrew TEE